Aquestive Therapeutics, Inc.
AQST
$5.39
$0.316.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.82M | 14.45M | 13.02M | 12.81M | 10.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.82M | 14.45M | 13.02M | 12.81M | 10.00M |
| Cost of Revenue | 4.02M | 3.47M | 5.84M | 4.51M | 4.56M |
| Gross Profit | 9.80M | 10.98M | 7.18M | 8.30M | 5.44M |
| SG&A Expenses | 14.06M | 10.98M | 32.82M | 15.25M | 12.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.04M | 18.65M | 41.85M | 24.29M | 21.37M |
| Operating Income | -8.22M | -4.20M | -28.84M | -11.48M | -11.37M |
| Income Before Tax | -22.86M | -8.06M | -31.86M | -15.45M | -13.55M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.86M | -8.06M | -31.86M | -15.45M | -13.55M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.86M | -8.06M | -31.86M | -15.45M | -13.55M |
| EBIT | -8.22M | -4.20M | -28.84M | -11.48M | -11.37M |
| EBITDA | -8.09M | -4.09M | -28.68M | -11.34M | -11.23M |
| EPS Basic | -0.18 | -0.07 | -0.26 | -0.14 | -0.14 |
| Normalized Basic EPS | -0.06 | -0.04 | -0.16 | -0.09 | -0.09 |
| EPS Diluted | -0.18 | -0.07 | -0.26 | -0.14 | -0.14 |
| Normalized Diluted EPS | -0.06 | -0.04 | -0.16 | -0.09 | -0.09 |
| Average Basic Shares Outstanding | 124.99M | 122.61M | 121.97M | 110.58M | 99.33M |
| Average Diluted Shares Outstanding | 124.99M | 122.61M | 121.97M | 110.58M | 99.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |